GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: A Review.

Authors

Sarah Rahni, Edward Lebovics, William H Frishman, Wilbert S Aronow

Published in

Cardiology in review. Nov 03, 2026. Epub Nov 03, 2026.

Abstract

Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity and have more recently demonstrated clinically important effects across the cardiometabolic spectrum, including metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, and atherosclerotic cardiovascular disease. Earlier cardiovascular outcome trials established reductions in major adverse cardiovascular events by way of injectable forms in patients with diabetes, while newer evidence has expanded these findings to oral semaglutide and to other patient populations. This review summarizes the hepatic, cardiovascular, and heart-failure evidence for glucagon-like peptide-1 receptor agonists-based therapies and discusses remaining clinical uncertainties and future directions.

PMID:
42975978
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.